Batoclimab, an FcRn antagonist, also showed an improvement in visual acuity and walking time in NMOSD patients with acute myelitis and/or optic neuritis in an open-label, dose-escalation phase 1b study [11]. This evidence concerns the gene FCGRT and optic neuritis.